Esperance Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- Esperance Pharmaceuticals Inc
- Target Recruit Count
- 49
- Registration Number
- NCT01485848
- Locations
- 🇺🇸
Investigational Site Number 840004, Middletown, Ohio, United States
🇺🇸Investigational Site Number 840003, Seattle, Washington, United States
🇺🇸Investigational Site Number 840503, Bozeman, Montana, United States
Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid TumorsAdvanced Solid Tumors
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Esperance Pharmaceuticals Inc
- Target Recruit Count
- 38
- Registration Number
- NCT00949559
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸TGEN Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath